Deep Offshore Wind Sized Up

Source: CNET, Candace Lombardi (2/23/11)

"Deep offshore wind could produce energy for $0.08–$0.10/KW within 10 years."

Deep offshore wind could produce energy for $0.08–$0.10 per kilowatt within 10 years, according to a report released today from the University of Maine and DeepCWind.org. The extensive report was funded with a $1 million grant from the DOE.

More interesting than how inexpensive offshore wind might become is the legal challenge such an undertaking could face.

In addition to a feasibility study for the Maine's coastal region in particular, the report delves into what the U.S. government and private companies may or may not be able to build in terms of deep offshore wind sites with an interconnection to a common grid, or with a series of independent grids.

Things become complicated depending on whether the offshore pilings and turbines were foreign made and how they're connected, though this could actually be a boon to U.S. manufacturers.

Three types of deep offshore wind designs are under development at the UOM Deepwater Offshore Wind Test Site.

The report asserts that deep offshore wind farms attached to the seabed could legally be treated as U.S. "ports," while turbines built as floating entities could be treated as "vessels," both of which are subject to Jones Act (aka the Merchant Marine Act of 1920) and other maritime regulations and cabotage laws. The report states one cabotage law dictates that "75% of the crew on U.S.-flagged vessels be U.S. citizens and/or permanent residents."

Under certain circumstances, the Defense Secretary can waive cabotage laws. Companies can petition for waivers—and have succeeded in some historical situations—but the process is controversial, costly and time-consuming.

The report also found that deep offshore wind sites would involve the jurisdiction of more than 12 U.S. agencies—from the EPA to the Border Patrol division of Homeland Security.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.